[go: up one dir, main page]

WO2008152015A1 - Composition destinée à atténuer les difficultés fonctionnelles liées aux affections du cartilage articulaire - Google Patents

Composition destinée à atténuer les difficultés fonctionnelles liées aux affections du cartilage articulaire Download PDF

Info

Publication number
WO2008152015A1
WO2008152015A1 PCT/EP2008/057151 EP2008057151W WO2008152015A1 WO 2008152015 A1 WO2008152015 A1 WO 2008152015A1 EP 2008057151 W EP2008057151 W EP 2008057151W WO 2008152015 A1 WO2008152015 A1 WO 2008152015A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
functional
oral administration
weight
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/057151
Other languages
English (en)
Inventor
Julian Agut Sanchez
Carlos Fernandez Navarro
Gabriel Espelleta Gil
Miquel Junca Riuro
Josep Junca Busquets
Ferran Junca Riuro
Jaime MELENDO BAÑOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Masterfarm SL
Original Assignee
Masterfarm SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Masterfarm SL filed Critical Masterfarm SL
Publication of WO2008152015A1 publication Critical patent/WO2008152015A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/145—Acids, anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/26—Proteins
    • A21D2/261—Animal proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
    • A23C9/1544—Non-acidified gels, e.g. custards, creams, desserts, puddings, shakes or foams, containing eggs or thickening or gelling agents other than sugar; Milk products containing natural or microbial polysaccharides, e.g. cellulose or cellulose derivatives; Milk products containing nutrient fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a composition comprising polymers of protein origin or cellulose, acrylic or carbohydrate derivatives for the improvement of functional difficulties which are a result of articular cartilage disorders.
  • the present invention relates to uses of the mentioned composition and to functional foods and food supplements comprising it.
  • gelatine hydrolysates are also useful as coadjuvants in the treatments intended to compensate the calcium deficit and that they are also useful in the treatment and prevention of hip dysplasia in dogs as described in patent document ES2104507.
  • the inventors of the present invention developed a high-purity enzymatic collagen hydrolysate with a better bioavailability due to its lower molecular weight (between 5000 and 20000 daltons).
  • This hydrolysate is distributed under the trade name Colatech® and a study was conducted with it in 100 healthy volunteers, this collagen being administered in a dose of 10 g per day to 50 of them and to the other 50 volunteers a dose of 1 .5 g per day of glucosamine sulphate, a product widely used both in Europe and in the United States at this dose for the treatment of articular disorders in general.
  • antioxidants such as lycopene obtained from tomato, resveratrol which can be obtained from Yucca schidigera and even vitamin C are being used as natural anti-inflammatory agents (Riso P, Visioli F, Grande S, Guarneri S, Gardana C, Simonetti P, Porrini M. Effect of a tomato-based drink on markers of inflammation, immunomodulation, and oxidative stress, J. Agric Food Chem. 2006 Apr 5; 54 (7): 2563-6; Liu X, Qu D, he F, Lu Q, Wang J, Cai D. Effect of Lycopene on the vascular endothelial function and expression of inflammatory agents in hyperhomocysteinemic rats, Asia Pac J Clin Nutr.
  • Natural bioflavonoids such as luteolin, naringin, quercetin, apigenin and genistein are also being widely used in dietary or food supplements due to their antiinflammatory action allowing their application in different disorders presenting inflammation (Nam N. H., Naturally occurring NF-kappaB inhibitors, Mini Rev. Med. Chem. 2006 Aug; 6 (8):945-51 ; Kumazawa Y. Kawaguchi K. Takimoto H., lmmunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha, Curr. Pharm. Des. 2006,12 (32); 4271 -9; Ruiz P. A.
  • Haller D. Functional diversity of flavonoids in the inhibition of the proinflammatory NF-kappaB, IRF, and Akt signaling pathways in murine intestinal epithelial cells, J. Nutr. 2006 Mar;136 (3); 664-71 ; Ruiz PA, Braune A, Holziwimmer G, Quintanilla - Fend L, Haller D., Quercetin inhibits TNF-induced NF-kappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells, J.Nutr. 2007 May; 137 (5); 1208 - 15).
  • Collagen has also been used in the field of food supplements to obtain preparations favouring the recovery of cartilage in animals suffering from diseases linked to this type of tissue.
  • a food supplement must be understood as any additional dietary intake which is consumed orally and contains a "food ingredient" intended to supplement the diet.
  • Some examples of dietary or food supplements are vitamins, minerals, herbs (a single herb or a mixture of several herbs), other botanical products, amino acids and food components such as enzymes.
  • Food supplements are generally distributed in the form of different presentations such as pastilles, capsules, soft gelatine capsules, gelatine capsules, liquids and powders.
  • Functional foods are nowadays also becoming known in the nutrition field. Functional foods are considered to be those foods which are consumed as part of a normal diet and contain biologically active components offering health benefits and reducing the risk of suffering from diseases. Foods containing certain minerals, vitamins, fatty acids or dietary fibre, foods to which biologically active substances such as phytochemicals or other antioxidants have been added, and probiotics, having live cultures of beneficial microorganisms, are emphasized among some examples of functional foods. Some yoghurts with probiotics, some margarines enriched with sterol esters and eggs rich in omega-3-type fatty acids are examples of functional foods.
  • hyaluronic acid When hyaluronic acid is associated with a polymer of protein origin or cellulose, acrylic or carbohydrate derivatives, hydrogen bonds are formed between the structure of the polymer, for example, of the collagen hydrolysate (amino and hydroxyl groups capable of forming this type of bond) and the hyaluronic acid molecule, favouring the passage of the latter through cell membranes and subsequently improving its absorption and causing an improvement in its activity.
  • collagen hydrolysate amino and hydroxyl groups capable of forming this type of bond
  • the polymer is a cellulose derivative, being an enzymatic collagen hydrolysate.
  • the composition for oral administration according to the invention is characterized in that it can further comprise other functional ingredients such as natural bioflavonoids and antioxidants.
  • the enzymatic collagen hydrolysate preferably has a molecular weight comprised between 1 ,000 and 50,000 daltons.
  • the composition for oral administration comprises from 96% to 99.5% by weight of enzymatic collagen hydrolysate, from 0.25% to 0.60% by weight of hyaluronic acid, from 1.0% to 2.5% of antioxidant agents and/or from 0.40% to 0.90% by weight of natural bioflavonoids being able to be incorporated to this association.
  • the natural bioflavonoids are chosen from the group consisting of quercetin, naringin, luteolin, apigenin, genistein, hesperidin or a mixture of at least two of them.
  • hyaluronic acid is in the form of sodium salt.
  • the composition comprises as an antioxidant at least one of those of the group consisting of beta-carotene, lycopene, resveratrol as well as their derivatives.
  • resveratrol refers to its cis and trans isomers and to mixtures thereof, as well to its derivatives by glycosylation of its hydroxyl groups; esterification of said hydroxyl groups or amides thereof in any of its isomeric forms.
  • the composition further comprises vitamin C, which will preferably be in the form of ascorbic acid.
  • composition for oral administration object of the invention further comprises mineral salts.
  • composition for oral administration further comprises B group vitamins and/or coenzymes, liposoluble vitamins and coenzyme Q10.
  • composition for oral administration according to the invention is also characterized in that it further comprises a coadjuvant compound selected from the group consisting of glucosamine sulphate and chondroitin sulphate.
  • composition for oral administration according to the invention is characterized in that it is in the form of a suspension.
  • composition for oral administration according to the invention is characterized in that it is in the form of a powder which is dispersible or soluble in an aqueous medium.
  • composition for oral administration according to the invention is also characterized in that it is in the form of a solution.
  • composition for oral administration according to the invention which is in the form of tablets or capsules is equally preferred.
  • Another object of the present invention is a functional food comprising a composition with polymers of protein origin or cellulose, acrylic or carbohydrate derivatives associated with natural bioflavonoids, antioxidants and hyaluronic acid in the form of acid or of their salts, as has been described above.
  • the functional food is preferably in the form of yoghurt, shake, custards, fruit juices, biscuits or energy bars.
  • Another object of the present invention is the use of the previously described compositions for the preparation of functional foods and food supplements for the improvement of the functional capacity and/or the quality of life of a mammal with functional difficulties derived from articular cartilage disorders.
  • the daily dose of the enzymatic collagen hydrolysate is comprised between 0.075 and 0.200 g per Kg of weight
  • the daily dose of bioflavonoids is comprised between 0.00025 and 0.001 g per Kg of weight
  • the daily dose of hyaluronic acid is comprised between 0.0001 and 0.001 g per Kg of weight
  • the daily dose of antioxidants is comprised between 0.00075 and 0.003 mg per Kg of weight.
  • the composition comprises vitamin C in a dose comprised between 0.0005 and 0.002 g per Kg of weight.
  • the use according to the invention is characterized in that the mammal with functional difficulties derived from articular cartilage disorders is a human.
  • the mammal with functional difficulties derived from articular cartilage disorders is an animal selected from the group consisting of dogs, cats and horses.
  • compositions object of the invention are effective due to the synergistic behaviour of their constituents
  • compositions and use examples thereof are detailed below by way of a non-limiting example. Tests which allow viewing the positive effects of these new compositions are also set forth.
  • TEST Comparison between compositions according to the invention and compositions according to the state of the art to determine their efficacy as products for the improvement of the functional capacity and/or the quality of life in mammals with difficulties derived from articular cartilage disorders.
  • a composition according to the invention and as detailed below was designed with the intention of reducing the daily dose of enzymatic collagen hydrolysate to be administered compared to the preparations existing on the market.
  • a typical dose of 10 grams a day was thus reduced to 7 grams, and hyaluronic acid, natural bioflavonoids and natural antioxidants were added to it in the average doses used of these products individually, the composition for the daily dose of said product being as follows:
  • Enzymatic collagen hydrolysate (Colatech®) 7.000 g
  • Hyaluronic acid 0.025 g Tomato extract with 2% Lycopene 0.075 g
  • the enzymatic collagen hydrolysate used has a high purity, i.e., it comprises 99% by weight of hydrolysate of the dry raw material product. Likewise, the molecular weight of said enzymatic collagen hydrolysate is comprised between
  • composition As a base, a suspension was prepared which was stabilized with different pharmaceutical quality excipients and it was suitably flavoured for the purpose of facilitating the consumption thereof.
  • EXAMPLE 1 Functional food in the form of yoghurt.
  • Enzymatic collagen hydrolysate (Colatech®) 7.000 g
  • Tomato concentrate with 2% Lycopene 0.075 g Vitamin C 0.060 g
  • Skimmed milk powder 12.000 g
  • a chocolate dessert with the following composition has been prepared:
  • Enzymatic collagen hydrolysate (Colatech®) 7.000 g
  • Tomato concentrate with 2% Lycopene 0.075 g Vitamin C 0.060 g
  • Pregelatinized corn starch 10.000 g Carrageenan 4.000 g
  • EXAMPLE 3 Food supplement in the form of a vial that is drinkable or can be diluted in aqueous medium and with raspberry flavour.
  • liquid presentation indicated below has been prepared to be taken in 30 g vials, either directly or diluted in water.
  • Enzymatic collagen hydrolysate (Colatech®) 23.334 g
  • Tomato concentrate with 2% Lycopene 0.250 g Vitamin C 0.200 g
  • Antifoam AF 0.040 g Colloidal silicon dioxide 0.02O g
  • EXAMPLE 4 Food supplement in the form of a powder and with strawberry flavour.
  • a mixture of powders has been prepared which can be packaged in jars adding a measuring device allowing the dosing of about 12 g in order to take the product once it has been dispersed in half a glass of water. It can also be packaged in single-dose paper-aluminium-polythene sachets whereby carrying the daily dose to be taken is favoured.
  • Enzymatic collagen hydrolysate (Colatech®) 58.344 g
  • Hyaluronic acid 0.208 g
  • Natural bioflavonoids 0.25O g
  • Vitamin C 0.50O g
  • Vitamin B1 Thiamine HCI 0.02O g
  • Vitamin B2 Raboflavin 0.02O g
  • Vitamin B6 (Pyridoxine HCI) 0.020 g
  • Vitamin B5 (Calcium pantothenate) 0.06O g
  • EXAMPLE 5 Food supplement in the form of a vial that is drinkable or can be diluted in aqueous medium and with vanilla flavour.
  • the liquid presentation indicated below has been prepared to be taken in 30 g vials, either directly or diluted in water.
  • EXAMPLE 6 Food supplement in the form of a vial that is drinkable or can be diluted in aqueous medium and with wild berry flavour.
  • compositions for oral administration comprising an enzymatic collagen hydrolysate or other types of polymer or protein hydrolysates capable of giving hydrogen bonds associated with hyaluronic acid or its salts, and to which natural bioflavonoids and antioxidants can be incorporated, also preferably comprise vitamin C.
  • the vitamin C used can be in its acid or ascorbic acid form; or in the form of acid salts, such as sodium ascorbate or calcium ascorbate.
  • B group vitamins such as vitamins B1 , B2, B6 and B5, as well as any pharmaceutical quality flavouring or flavour enhancer, is also contemplated in order to provide the compositions with improved organoleptic properties.
  • liposoluble vitamins vitamins A, D, E
  • antiradical agent coenzyme Q10 can also be added.
  • compositions can contain mineral salts, such as magnesium carbonate.
  • mineral salts such as magnesium carbonate.
  • Other mineral salts of calcium, magnesium, sodium, potassium, selenium, copper, zinc, molybdenum, etc. can be added, the intake of these types of compounds thus being modulated according to the requirements or deficiencies of the mammals to which the compositions are to be administered.
  • Hyaluronic acid can be used in the form of acid or also in the form of its salts, preferably the sodium salt, according to availability.
  • the natural bioflavonoids used comprise at least one of the following compounds: quercetin, naringin, luteolin, apigenin, genistein and hesperidin, in different proportions according to the plant source of origin.
  • compositions according to the invention can contain plant extracts or products of animal origin, traditionally used to alleviate functional difficulties due to articular cartilage disorders.
  • glucosamine sulphate or chondroitin sulphate which are also widely used for dysfunctions derived from cartilage problems, can be added to said compositions.
  • compositions and/or functional foods and/or food supplements indicated above allow, as is deduced from the previous test, increasing the rate of action with regard to the improvement of the functional capacity and/or the quality of life of people or animals that are physically or socially impaired due to articular cartilage disorders.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition destiné à être administrée par voie orale, comprenant un hydrolysat enzymatique de collagène ou d'autres types de polymères ou d'hydrolysats protéiques permettant d'obtenir des liaison hydrogène avec l'acide hyaluronique sous forme d'acide ou d'un de ses sels, pouvant également comprendre des bioflavonoïdes et des antioxydants naturels. La composition est utilisée pour la préparation d'aliments fonctionnels et de compléments alimentaires destinés à améliorer la capacité fonctionnelle et/ou la qualité de vie d'un mammifère souffrant de difficultés fonctionnelles liées à des affections du cartilage articulaire.
PCT/EP2008/057151 2007-06-15 2008-06-09 Composition destinée à atténuer les difficultés fonctionnelles liées aux affections du cartilage articulaire Ceased WO2008152015A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200701716 2007-06-15
ES200701716A ES2319049B1 (es) 2007-06-15 2007-06-15 Composicion que comprende hidrolizado de colageno y acido hialuronico para la mejora de dificultades funcionales consecutivas a alteraciones de los cartilagos articulares.

Publications (1)

Publication Number Publication Date
WO2008152015A1 true WO2008152015A1 (fr) 2008-12-18

Family

ID=39766672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/057151 Ceased WO2008152015A1 (fr) 2007-06-15 2008-06-09 Composition destinée à atténuer les difficultés fonctionnelles liées aux affections du cartilage articulaire

Country Status (2)

Country Link
ES (1) ES2319049B1 (fr)
WO (1) WO2008152015A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20111925A1 (it) * 2011-10-25 2013-04-26 Apharm Srl Composizioni a base di acido ialuronico e fibre naturali per uso orale atte ad incrementare l'attivita' peristaltica intestinale.
DE102017006532A1 (de) * 2017-07-11 2019-01-17 Carlo Bermes Arzneimittel und Getränk zur Verbesserung von Gelenk- und Knochenleiden

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211143B1 (en) * 1998-03-25 2001-04-03 Masterfarm S.L. Preparation and method for increasing cartilaginous mass of joints in a mammal
US20020068718A1 (en) * 2000-10-03 2002-06-06 Pierce Scott W. Chondroprotective/restorative compositions and methods of use thereof
US6476005B1 (en) * 1998-03-24 2002-11-05 George D. Petito Oral and injectable nutritional composition
US20020173484A1 (en) * 2001-05-18 2002-11-21 Harry Leneau Ingestion of hyaluronic acid for improved joint function and health
US20030069171A1 (en) * 1998-03-24 2003-04-10 Petito George D. Nutritional composition for the treatment of connective tissue
WO2003034993A2 (fr) * 2001-10-23 2003-05-01 Petito George D Composition et procede de croissance, protection et reparation de tissus et cellules
US20050084518A1 (en) * 2003-10-20 2005-04-21 Medicaraise Health food containing hyaluronic acid and dermatan sulfate
WO2006116452A1 (fr) * 2005-04-22 2006-11-02 Molecular Regenix, Llc Composition nutritionnelle comprenant de l'acide hyaluronique et une superoxyde dismutase et procédés de fabrication et d'utilisation de celle-ci
US20070155666A1 (en) * 2001-01-24 2007-07-05 Ahmad Alkayali Canine and equine collagen joint health supplement
WO2007090504A1 (fr) * 2006-02-10 2007-08-16 Masterfam, S.L. Collagene hydrolyse et ses utilisations
WO2007122179A1 (fr) * 2006-04-21 2007-11-01 Diana Naturals Hydrolysat de cartilage avien, procédé de préparation et utilisation

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476005B1 (en) * 1998-03-24 2002-11-05 George D. Petito Oral and injectable nutritional composition
US20030069171A1 (en) * 1998-03-24 2003-04-10 Petito George D. Nutritional composition for the treatment of connective tissue
US6211143B1 (en) * 1998-03-25 2001-04-03 Masterfarm S.L. Preparation and method for increasing cartilaginous mass of joints in a mammal
US20020068718A1 (en) * 2000-10-03 2002-06-06 Pierce Scott W. Chondroprotective/restorative compositions and methods of use thereof
US20070155666A1 (en) * 2001-01-24 2007-07-05 Ahmad Alkayali Canine and equine collagen joint health supplement
US20020173484A1 (en) * 2001-05-18 2002-11-21 Harry Leneau Ingestion of hyaluronic acid for improved joint function and health
WO2003034993A2 (fr) * 2001-10-23 2003-05-01 Petito George D Composition et procede de croissance, protection et reparation de tissus et cellules
US20050084518A1 (en) * 2003-10-20 2005-04-21 Medicaraise Health food containing hyaluronic acid and dermatan sulfate
WO2006116452A1 (fr) * 2005-04-22 2006-11-02 Molecular Regenix, Llc Composition nutritionnelle comprenant de l'acide hyaluronique et une superoxyde dismutase et procédés de fabrication et d'utilisation de celle-ci
WO2007090504A1 (fr) * 2006-02-10 2007-08-16 Masterfam, S.L. Collagene hydrolyse et ses utilisations
WO2007122179A1 (fr) * 2006-04-21 2007-11-01 Diana Naturals Hydrolysat de cartilage avien, procédé de préparation et utilisation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20111925A1 (it) * 2011-10-25 2013-04-26 Apharm Srl Composizioni a base di acido ialuronico e fibre naturali per uso orale atte ad incrementare l'attivita' peristaltica intestinale.
DE102017006532A1 (de) * 2017-07-11 2019-01-17 Carlo Bermes Arzneimittel und Getränk zur Verbesserung von Gelenk- und Knochenleiden
WO2019011911A1 (fr) 2017-07-11 2019-01-17 Bermes Carlo Médicament et boisson pour l'amélioration de maladies articulaires et osseuses

Also Published As

Publication number Publication date
ES2319049B1 (es) 2010-02-10
ES2319049A1 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
CN104837369B (zh) 用于增强EGCg对减缓骨骼肌损失的作用的方法
US20160361291A1 (en) Methods for increasing skeletal muscle protein synthesis using green tea extract
EP2859896A1 (fr) Compositions pharmaceutiques pour le traitement des troubles musculaires
JP2005537241A (ja) 骨形成促進薬の製造のためのヘスペリジンまたはそのいずれか一つの誘導体の使用
US20110160136A1 (en) Polyphenols for the treatment of cartilage disorders
JP2009051833A (ja) 関節痛改善用組成物、関節痛改善剤、あるいは食品
US20090022853A1 (en) Beverage
WO2008152015A1 (fr) Composition destinée à atténuer les difficultés fonctionnelles liées aux affections du cartilage articulaire
WO2022106410A1 (fr) Compositions et méthodes utilisant une combinaison d'oleuropéine et de quercétine à des fins d'utilisation dans la dégénerescence du cartilage
WO2015094767A1 (fr) Méthodes pour maintenir ou augmenter le poids corporel à l'aide d'extrait de thé vert décaféiné
US20250312307A1 (en) Compositions and methods using a combination of fisetin and quercetin for use in cartilage degeneration
US20250302855A1 (en) Compositions and methods using a combination of oleuropein and fisetin for use in cartilage degeneration
US20110263697A1 (en) Methods of Reducing Oxidative Modification of a Muscle Cell Protein
JP7457353B2 (ja) 軟骨細胞への分化促進剤、軟骨細胞の増殖促進剤および軟骨基質産生促進剤
EP4403178A1 (fr) Promoteur de différenciation en cellule cartilagineuse, promoteur de propagation de cellules cartilagineuses et promoteur de production de matrice cartilagineuse
KR20090064449A (ko) 신규한 기능식품용 및 약학적 조성물 및 관절 내 연골 분해 또는 연골 손상의 치료, 공동치료 또는 예방을 위한 이의 용도
DE102010053748B4 (de) Pharmazeutische Zusammensetzung zur Behandlung von Übergewicht
AU2023378255A1 (en) Compositions and methods using a combination of oleuropein and taurine for use in prevention or treatment of joint disorders
HK1212560B (en) Methods for enhancing the effect of egcg on mitigating skeletal muscle loss
HK1081866B (en) Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08760719

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08760719

Country of ref document: EP

Kind code of ref document: A1